23andMe Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Value Chain Analysis for Deeper Insight
This 23andMe Value Chain Analysis gives you a clear, structured view of how the company creates value through its support and primary activities. The page already shows a real preview of the actual report content, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
23andMe's firm infrastructure is built on privacy, consent, legal compliance, and data governance, because trust is the core asset in both consumer testing and research licensing. The company says its database covers more than 15 million customers, so any breach in controls could hurt both sales and research revenue. In FY2025, that makes governance not back-office work, but a direct driver of value.
Human Resource Management
In FY2025, 23andMe reported about $219 million in revenue and needed a lean mix of genetics, bioinformatics, software, regulatory, and customer support talent. That skill set helps keep report quality high while the lab, data, and privacy teams stay aligned. With genetic testing tied to sensitive health data, strong hiring and training are a direct control on error and compliance risk.
Technology Development
Technology development is 23andMe's core asset: its data pipelines, ancestry and health algorithms, secure account tools, and research analytics all run from the same genetic dataset. In fiscal 2025, the Company generated about $220 million in revenue, showing how software and data work drive both consumer reports and research value. That same platform also supports drug-discovery partnerships, so each upgrade can improve reports, lift data quality, and expand the research business at once.
Procurement
Procurement at 23andMe covers saliva kits, lab consumables, cloud services, and shipping. In FY2025, tight buying terms matter because every kit, reagent, and server minute flows through a mostly fixed test-to-report pipeline, so small price cuts can lift gross margin fast. Strong supplier control also helps keep turnaround times steady as volume changes.
23andMe's FY2025 Edge: Privacy, Data Control, and Platform Strength
In FY2025, 23andMe's support activities stayed centered on privacy, compliance, and data control, because its value depends on protecting genetic data. With about $219 million in revenue and more than 15 million customer profiles, firm infrastructure and technology work were as important as sales. Hiring, training, and supplier control all fed report quality, turnaround time, and research value.
| Support activity | FY2025 signal |
|---|---|
| Infrastructure | Privacy-led, data-heavy model |
| HR | Genetics, bioinformatics, compliance talent |
| Tech | Platform linked to 15M+ profiles |
| Procurement | Controls kit, lab, and cloud costs |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Inbound logistics at 23andMe start with shipping saliva kits to customers and getting returned samples back into the lab. Every kit, sample, and consent record has to be tracked tightly because that sample is the input for genotyping, ancestry reports, and research use. In FY2025, this flow stayed central to 23andMe's business, because any missed kit or consent error can stop downstream processing.
Operations
Operations turn each saliva kit into ancestry, health predisposition, and trait reports through genotyping, quality control, and secure data handling. In FY2025, 23andMe still had more than 15 million genotyped customers, so lab speed and data integrity stayed core value drivers. Strong QC lowers reruns and supports trust, which is what turns a low-cost sample into a paid digital product.
Outbound Logistics
23andMe's outbound logistics are mostly digital: ancestry and health reports are delivered through its online platform, so there is no broad physical network for result delivery. That cuts fulfillment steps and keeps marginal delivery cost low. In FY2025, this lets the Company scale report delivery without adding warehouses, trucks, or last-mile carriers.
Marketing and Sales
23andMe's marketing and sales are built on direct-to-consumer branding, online checkout, and simple education around ancestry and health reports. The model depends on trust and clear claims because the product is sold online and often bought once, so conversion matters as much as awareness. In fiscal 2025, the company kept pushing lower-cost digital reach while the broader business worked through steep revenue pressure and a shrinking customer base.
Service
Service at 23andMe covers support, account access, report help, and privacy controls. With more than 15 million customers, clear answers and easy controls matter because users are sharing highly sensitive DNA data. Good service also helps keep consent active for research, which supports the company's data pool and long-term value.
23andMe's Digital-First Model Powers 15M+ Genotyped Customers
23andMe's primary activities are built around kit fulfillment, lab genotyping, digital report delivery, and customer support. In FY2025, the Company still had more than 15 million genotyped customers, so every step from sample intake to report access stayed core to value creation. Its model keeps physical handling low and shifts most delivery to software.
| FY2025 item | Value |
|---|---|
| Genotyped customers | 15M+ |
| Report delivery | Digital |
Preview the Actual Deliverable
23andMe Reference Sources
This is the actual 23andMe Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version. The preview below is taken directly from the complete report, so what you see here is exactly what you'll get. Unlock the full, detailed analysis after checkout and download the same file in its entirety.
Frequently Asked Questions
It creates value by turning 1 saliva sample into 3 customer report categories and then reusing consented data in 2 revenue streams. The consumer side covers ancestry, health predispositions, and traits. The research side can support pharma and biotech partnerships, so the same dataset is monetized at both the customer and partner level.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.